StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS)

Analysts at StockNews.com initiated coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research note issued to investors on Monday. The brokerage set a “sell” rating on the stock.

SYRS has been the subject of a number of other research reports. Brookline Capital Management reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. TD Cowen reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. HC Wainwright reissued a “neutral” rating and issued a $1.00 price objective (down previously from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $3.33.

Syros Pharmaceuticals Trading Down 0.5 %

Shares of SYRS opened at $0.20 on Monday. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.25 and a quick ratio of 2.25. Syros Pharmaceuticals has a 1-year low of $0.18 and a 1-year high of $8.17. The stock has a market cap of $5.44 million, a price-to-earnings ratio of -0.07 and a beta of 1.34. The firm has a 50 day simple moving average of $1.13 and a 200-day simple moving average of $2.82.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its earnings results on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.08. During the same period last year, the firm posted ($1.35) EPS. Equities analysts forecast that Syros Pharmaceuticals will post -2.94 EPS for the current fiscal year.

Insiders Place Their Bets

In other Syros Pharmaceuticals news, Director Nancy A. Simonian sold 134,713 shares of Syros Pharmaceuticals stock in a transaction on Monday, November 25th. The shares were sold at an average price of $0.27, for a total value of $36,372.51. Following the transaction, the director now owns 41,070 shares in the company, valued at $11,088.90. This trade represents a 76.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 12.26% of the stock is owned by corporate insiders.

Institutional Trading of Syros Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Acadian Asset Management LLC boosted its holdings in Syros Pharmaceuticals by 101.5% in the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after acquiring an additional 17,416 shares during the last quarter. Certuity LLC acquired a new position in shares of Syros Pharmaceuticals in the 2nd quarter valued at about $109,000. Exome Asset Management LLC grew its holdings in shares of Syros Pharmaceuticals by 87.6% during the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after purchasing an additional 139,400 shares during the period. Finally, GSA Capital Partners LLP acquired a new stake in Syros Pharmaceuticals during the 3rd quarter worth approximately $34,000. 91.47% of the stock is currently owned by institutional investors and hedge funds.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.